secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001193125-25-167089
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 1.01, 3.02, 9.01, 5.02, 3.03, 5.01, 5.03, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis
--------------------------------------------------------------------------------

- Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.
- Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.
- Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.
- CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.
- PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/0001193125-25-167089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525167089/d66290d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-167089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer